Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer
Cancer Chemotherapy and Pharmacology Aug 28, 2017
Danno K, et al. – The safety and efficacy of adjuvant oxaliplatin plus oral capecitabine (XELOX) in Japanese patients with curatively resected stage III colon cancer (MCSCO–1024), were appraised in this study. Based on the data obtained, for this group of patients, adjuvant XELOX was tolerable.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
